Uniqure N.v.
A gene therapy company developing one-time treatments for rare diseases, uniQure produced HEMGENIX, the first FDA-approved gene therapy for hemophilia B, now sold worldwide by partner CSL Behring. Founded in 1998 as Amsterdam Molecular Therapeutics by scientists from Amsterdam's Academic Medical Center, it renamed itself uniQure—a play on "unique cures." It also developed Glybera, the first gene therapy approved in the Western world, and its lead experimental candidate targets Huntington's disease.
Granted 1.57M · Sold 1.28M
Granted 381.4K · Sold 177.8K
Granted 154.2K · Sold 53.2K
Granted 189.3K · Sold 25.9K
Granted 183.4K · Sold 23.9K
Granted 167.0K · Sold 33.8K
Granted 162.0K · Sold 46.3K
Granted 19.8K · Sold 15.9K
Granted 64.7K · Sold 5.9K
Granted 64.5K · Sold 5.9K
Granted 63.3K · Sold 5.9K
Granted 260.4K · Sold 158.0K
Granted 57.8K · Sold 9.6K
Granted 77.1K · Sold 33.8K
Granted 10.1K · Sold 12.4K
Granted 55.4K · Sold 12.1K
Granted 50.6K · Sold 10.8K
Granted 45.3K · Sold 9.8K
Granted 42.9K · Sold 9.0K
Granted 166.6K · Sold 133.2K
Granted 108.5K · Sold 68.1K
Granted 140.7K · Sold 140.7K
Granted 20.9K · Sold 591
Granted 52.8K · Sold 48.6K
Granted 12.5K · Sold 32.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kapusta Matthew CCEO, Managing Director, Director · 165 transactions | — | 519.2K | 1.57M | — | 1.28M |
| Klemt ChristianChief Financial Officer · 53 transactions | — | 238.6K | 381.4K | — | 177.8K |
| Abi-Saab WalidChief Medical Officer · 12 transactions | — | 168.2K | 154.2K | — | 53.2K |
| Dolmetsch RicardoPresident, R&D · 13 transactions | — | 163.4Kas of Sep 2023 | 189.3K | — | 25.9K |
| Zelenkofske StevenChief Medical Officer · 3 transactions | — | 159.5Kas of Jun 2018 | 183.4K | — | 23.9K |
| Potts JeannetteChief Legal Officer · 10 transactions | — | 133.2K | 167.0K | — | 33.8K |
| Caloz PierreChief Operating Officer · 16 transactions | — | 115.7Kas of Jun 2024 | 162.0K | — | 46.3K |
| O'Keefe KylieChief Customer & Strat Officer · 2 transactions | — | 108.9K | 19.8K | — | 15.9K |
| Firuta Paul EChief Commercial Officer · 3 transactions | — | 93.8Kas of Jan 2018 | 64.7K | — | 5.9K |
| Garen JonathanChief Business Officer · 3 transactions | — | 93.6Kas of Jan 2018 | 64.5K | — | 5.9K |
| Cantor Maria ESVP, Investor Rel. & Comm. · 3 transactions | — | 92.4Kas of Jan 2018 | 63.3K | — | 5.9K |
| Kuta Alexander Edward IIIExecutive VP, Operations · 67 transactions | — | 90.4Kas of Mar 2023 | 260.4K | — | 158.0K |
| van Deventer SanderEVP, Research & Product Dev. · 10 transactions | — | 71.5Kas of Mar 2020 | 57.8K | — | 9.6K |
| Balachandran MadhavanDirector · 26 transactions | — | 49.6K | 77.1K | — | 33.8K |
| Schaffer DavidDirector · 7 transactions | — | 47.0Kas of Feb 2020 | 10.1K | — | 12.4K |
| Springhorn Jeremy P.Director · 20 transactions | — | 43.3K | 55.4K | — | 12.1K |
| Meek David D.Director · 18 transactions | — | 39.7K | 50.6K | — | 10.8K |
| Post Leonard EDirector · 13 transactions | — | 35.5K | 45.3K | — | 9.8K |
| Jacques Rachelle SuzanneDirector · 11 transactions | — | 33.9K | 42.9K | — | 9.0K |
| Gut RobertDirector · 40 transactions | — | 32.3K | 166.6K | — | 133.2K |
| Kaye JackDirector · 34 transactions | — | 26.0K | 108.5K | — | 68.1K |
| Petry HaraldChief Scientific Officer · 12 transactions | — | 21.5Kas of Jun 2017 | 140.7K | — | 140.7K |
| McMillan Scott T.Chief Operating Officer · 4 transactions | — | 20.4Kas of Jan 2019 | 20.9K | — | 591 |
| Soteropoulos PaulaDirector · 31 transactions | — | 20.2Kas of Jun 2024 | 52.8K | — | 48.6K |
| Astley-Sparke PhilipDirector · 18 transactions | — | 9.9Kas of Mar 2021 | 12.5K | — | 32.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.36M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.